Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 21, 2024 07:00 ET | Source: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals Presents Late-Breaking Translational Data on Eblasakimab in COPD at the American Thoracic Society International Conference

Translational data presented during a late-breaker poster session from a head-to-head study of eblasakimab and dupilumab in a human tissue model of COPD indicates that eblasakimab performed better...
May 09, 2024 07:00 ET | Source: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

Positive interim data readout from 22 patients in TREK-DX study of eblasakimab showed unprecedented efficacy data compared to prior atopic dermatitis (AD) studies with biologics: 60.0% of...
May 07, 2024 07:30 ET | Source: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals to Present Additional Data From Interim Analysis of TREK-DX Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients During Virtual KOL Event

New positive data from an additional analysis of dupilumab-experienced patients treated with eblasakimab 400mg, weekly over 16 weeks further support the recent finding that some AD patients may...
May 02, 2024 09:00 ET | Source: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals Announces Expansion of its Collaboration With Zenyaku to Investigate the Biology Underlying Differential Effects of Eblasakimab Compared to Other Biologics

New research collaboration will explore the differentiation of eblasakimab's mechanism of action versus biologic therapies for atopic dermatitis (AD), dupilumab and lebrikizumab.The findings will...
April 30, 2024 07:00 ET | Source: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals to Host KOL Panel Discussion on Treatment Options for Atopic Dermatitis Patients With an Inadequate Response to Dupilumab

ASLAN management will present new data from the interim analysis of the TREK-DX studyRegister here to attend the webinar event on May 7, 2024 at 8:00 AM ET SAN MATEO, Calif. and SINGAPORE,...
April 24, 2024 07:00 ET | Source: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals Announces Late Breaking Abstract on Eblasakimab in COPD Accepted for Presentation at the American Thoracic Society International Conference

SAN MATEO, Calif. and SINGAPORE, April 24, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative...
April 22, 2024 08:45 ET | Source: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients

ASLAN Pharmaceuticals announces positive interim results from phase 2 study of eblasakimab in dupilumab-experienced atopic dermatitis patients
April 19, 2024 17:10 ET | Source: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals Announces Receipt of Nasdaq Notice

SAN MATEO, Calif. and SINGAPORE, April 19, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative...
April 12, 2024 08:00 ET | Source: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

In a preliminary review of blinded data from the ongoing TREK-DX study, 45% (10/22) of patients achieved at least a 90% reduction in their EASI score (EASI-90) after 16 weeks. 56% (5/9) of patients...
March 27, 2024 08:07 ET | Source: ASLAN PHARMACEUTICALS LIMITED

Aslan Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disorders

SAN MATEO, Calif. and SINGAPORE, March 27, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceutical (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative...